Key Takeaways:
- Expected NIH funding cuts could push research institutions to scale back and startups to shut down or slow operations, reducing demand for life sciences space.
- Companies are addressing drug pricing and access pressures by investing in R&D and acquisitions to lower costs and improve consumer access.
- Venture capital (VC) funding in life sciences holds steady year over year, reflecting continued caution amid global uncertainty.